Phase 3b Study to Test the Safety and Effectiveness of an Adjuvanted Chikungunya Virus-like Particle Vaccine for Preventing Chikungunya Disease in Adolescents and Adults
Led by Bavarian Nordic · Updated on 2026-06-29
6144
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, immune response, and safety of the CHIKV VLP vaccine to prevent Chikungunya disease in adolescents and adults aged 12 years and older. This phase 3b study uses advanced infectious disease models and analytics to select regions and clinical sites, set study timelines, and optimize study parameters against local Chikungunya virus conditions to address challenges in assessing vaccine efficacy.
Participants will be randomly assigned to receive either the CHIKV VLP vaccine with an adjuvant or a placebo. The vaccine consists of a 0.8 mL intramuscular injection containing 40 g of CHIKV VLP adsorbed on aluminum hydroxide. The study includes two groups one receiving the active vaccine and one receiving placebo. It follows participants from 14 days after vaccination up to 1095 days to assess disease prevention and immune response.
During the study, participants will be monitored for confirmed acute, chronic, and severe Chikungunya disease cases. Safety is tracked by recording local and unsolicited adverse events up to 28 days postvaccination and serious or medically attended events throughout the study. Blood samples will measure antibody responses at three weeks postvaccination. The total study duration is up to three years, allowing detailed follow-up on vaccine effects and safety.
CONDITIONS
Brief Title
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Research Team
A
Anjali Chudasama, MPH M.Sc.
T
Tiffany Brockington
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Able and willing to provide informed consent (and assent if applicable) and willing to stay in the study for its entire duration
Male or nonpregnant female aged 12 years and older
In stable health with no hospital admission or major surgery in the last 30 days before vaccination
Women either not of childbearing potential or meeting specific pregnancy testing and contraception requirements
Willing to use acceptable contraception for at least 8 weeks after vaccination if applicable
You will not qualify if you...
Currently pregnant or breastfeeding
Participation or planned participation in another investigational clinical study within 30 days before vaccination and during the study, except certain observational studies
History of severe allergic reaction to any component of the investigational product
Prior receipt of any Chikungunya vaccine or participation in a prior interventional Chikungunya trial
Known immunodeficiency or immunosuppressive condition affecting vaccine response
Use of systemic immunomodulatory or immunosuppressive medications from 6 months before screening through 21 days after vaccination
Receipt or planned receipt of any vaccine from 30 days before vaccination through 21 days after vaccination
Unstable medical condition or acute illness within 14 days before vaccination
Medical or social condition impacting ability to comply with study procedures
Plans to travel or move away for more than 3 consecutive months during follow-up
Investigator or employee of study site or Bavarian Nordic with direct involvement in the study
Any other medical condition that could adversely impact participation or study conduct
Your Study Journey
Screening
Duration - Up to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single day
Participants receive a single intramuscular injection of either the CHIKV VLP vaccine or placebo.
1 visit (in-person)
Follow-up
Duration - Up to 1095 days
Participants are monitored for up to 1095 days postvaccination for Chikungunya disease occurrence and safety events, with blood samples collected to assess immune response.
Regular visits at scheduled intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
Sean R Bennett, James M McCarty, Roshan Ramanathan...
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
Jason S Richardson, Deborah M Anderson, Jason Mendy...